Dynavax Technologies Corporation (DVAX)
USD 11.76
(-5.88%)
USD 11.76
(-5.88%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 997.09 Million USD | 1.14% |
| 2022 | 985.85 Million USD | -5.14% |
| 2021 | 1.03 Billion USD | 194.18% |
| 2020 | 353.27 Million USD | 26.59% |
| 2019 | 279.06 Million USD | 32.33% |
| 2018 | 210.88 Million USD | -3.61% |
| 2017 | 218.78 Million USD | 99.48% |
| 2016 | 109.68 Million USD | -49.37% |
| 2015 | 216.63 Million USD | 56.65% |
| 2014 | 138.29 Million USD | -32.42% |
| 2013 | 204.62 Million USD | 46.42% |
| 2012 | 139.75 Million USD | 4.21% |
| 2011 | 134.1 Million USD | 59.17% |
| 2010 | 84.24 Million USD | 66.93% |
| 2009 | 50.47 Million USD | -44.31% |
| 2008 | 90.62 Million USD | -24.76% |
| 2007 | 120.44 Million USD | 17.07% |
| 2006 | 102.89 Million USD | 28.46% |
| 2005 | 80.09 Million USD | 8.75% |
| 2004 | 73.64 Million USD | 133.17% |
| 2003 | 31.58 Million USD | 0.34% |
| 2002 | 31.47 Million USD | 108.23% |
| 2001 | 15.11 Million USD | -48.91% |
| 2000 | 29.59 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 986.56 Million USD | -1.06% |
| 2024 Q2 | 1.01 Billion USD | 3.02% |
| 2023 Q3 | 972.93 Million USD | 3.9% |
| 2023 Q4 | 997.09 Million USD | 2.48% |
| 2023 Q2 | 936.43 Million USD | -3.45% |
| 2023 FY | 997.09 Million USD | 1.14% |
| 2023 Q1 | 969.92 Million USD | -1.62% |
| 2022 Q1 | 1 Billion USD | -2.91% |
| 2022 Q3 | 999.33 Million USD | -2.31% |
| 2022 Q4 | 985.85 Million USD | -1.35% |
| 2022 Q2 | 1.02 Billion USD | 1.39% |
| 2022 FY | 985.85 Million USD | -5.14% |
| 2021 Q2 | 647.9 Million USD | 32.19% |
| 2021 FY | 1.03 Billion USD | 194.18% |
| 2021 Q1 | 490.11 Million USD | 38.74% |
| 2021 Q4 | 1.03 Billion USD | 13.0% |
| 2021 Q3 | 919.71 Million USD | 41.95% |
| 2020 Q1 | 259.25 Million USD | -7.1% |
| 2020 Q4 | 353.27 Million USD | -0.03% |
| 2020 Q2 | 329.31 Million USD | 27.02% |
| 2020 Q3 | 353.39 Million USD | 7.31% |
| 2020 FY | 353.27 Million USD | 26.59% |
| 2019 Q3 | 301.01 Million USD | 12.71% |
| 2019 FY | 279.06 Million USD | 32.33% |
| 2019 Q1 | 296.6 Million USD | 40.65% |
| 2019 Q2 | 267.08 Million USD | -9.95% |
| 2019 Q4 | 279.06 Million USD | -7.29% |
| 2018 Q4 | 210.88 Million USD | -10.79% |
| 2018 Q2 | 263.86 Million USD | -10.66% |
| 2018 Q1 | 295.33 Million USD | 34.99% |
| 2018 FY | 210.88 Million USD | -3.61% |
| 2018 Q3 | 236.38 Million USD | -10.41% |
| 2017 Q4 | 218.78 Million USD | 0.44% |
| 2017 Q3 | 217.82 Million USD | 43.34% |
| 2017 Q2 | 151.96 Million USD | 37.99% |
| 2017 Q1 | 110.13 Million USD | 0.41% |
| 2017 FY | 218.78 Million USD | 99.48% |
| 2016 Q1 | 189.64 Million USD | -12.46% |
| 2016 FY | 109.68 Million USD | -49.37% |
| 2016 Q2 | 167.61 Million USD | -11.62% |
| 2016 Q3 | 139.29 Million USD | -16.89% |
| 2016 Q4 | 109.68 Million USD | -21.26% |
| 2015 Q1 | 112.16 Million USD | -18.89% |
| 2015 Q4 | 216.63 Million USD | -9.32% |
| 2015 FY | 216.63 Million USD | 56.65% |
| 2015 Q3 | 238.9 Million USD | 118.19% |
| 2015 Q2 | 109.49 Million USD | -2.38% |
| 2014 Q3 | 146.89 Million USD | -15.32% |
| 2014 Q4 | 138.29 Million USD | -5.86% |
| 2014 FY | 138.29 Million USD | -32.42% |
| 2014 Q1 | 193.58 Million USD | -5.39% |
| 2014 Q2 | 173.46 Million USD | -10.39% |
| 2013 Q1 | 119.62 Million USD | -14.4% |
| 2013 Q3 | 91.69 Million USD | -11.84% |
| 2013 Q4 | 204.62 Million USD | 123.15% |
| 2013 FY | 204.62 Million USD | 46.42% |
| 2013 Q2 | 104.01 Million USD | -13.05% |
| 2012 Q2 | 175.89 Million USD | 45.76% |
| 2012 Q3 | 164.82 Million USD | -6.3% |
| 2012 Q4 | 139.75 Million USD | -15.21% |
| 2012 Q1 | 120.67 Million USD | -10.01% |
| 2012 FY | 139.75 Million USD | 4.21% |
| 2011 Q3 | 64.71 Million USD | -13.05% |
| 2011 FY | 134.1 Million USD | 59.17% |
| 2011 Q1 | 65.5 Million USD | -22.25% |
| 2011 Q2 | 74.43 Million USD | 13.62% |
| 2011 Q4 | 134.1 Million USD | 107.21% |
| 2010 FY | 84.24 Million USD | 66.93% |
| 2010 Q2 | 71.67 Million USD | 61.86% |
| 2010 Q1 | 44.28 Million USD | -12.26% |
| 2010 Q3 | 61.79 Million USD | -13.8% |
| 2010 Q4 | 84.24 Million USD | 36.35% |
| 2009 Q1 | 78.14 Million USD | -13.77% |
| 2009 FY | 50.47 Million USD | -44.31% |
| 2009 Q4 | 50.47 Million USD | -18.13% |
| 2009 Q3 | 61.64 Million USD | -10.85% |
| 2009 Q2 | 69.14 Million USD | -11.51% |
| 2008 FY | 90.62 Million USD | -24.76% |
| 2008 Q3 | 87.55 Million USD | -9.68% |
| 2008 Q4 | 90.62 Million USD | 3.5% |
| 2008 Q2 | 96.93 Million USD | -7.97% |
| 2008 Q1 | 105.33 Million USD | -12.55% |
| 2007 Q4 | 120.44 Million USD | 36.88% |
| 2007 FY | 120.44 Million USD | 17.07% |
| 2007 Q2 | 98.48 Million USD | 13.15% |
| 2007 Q1 | 87.03 Million USD | -15.41% |
| 2007 Q3 | 87.99 Million USD | -10.65% |
| 2006 Q1 | 73.47 Million USD | -8.27% |
| 2006 Q4 | 102.89 Million USD | 36.28% |
| 2006 FY | 102.89 Million USD | 28.46% |
| 2006 Q3 | 75.49 Million USD | -1.47% |
| 2006 Q2 | 76.62 Million USD | 4.29% |
| 2005 FY | 80.09 Million USD | 8.75% |
| 2005 Q4 | 80.09 Million USD | 41.25% |
| 2005 Q3 | 56.7 Million USD | -11.87% |
| 2005 Q2 | 64.33 Million USD | -9.7% |
| 2005 Q1 | 71.25 Million USD | -3.25% |
| 2004 Q1 | 83.78 Million USD | 165.27% |
| 2004 FY | 73.64 Million USD | 133.17% |
| 2004 Q2 | 81.01 Million USD | -3.31% |
| 2004 Q3 | 79.07 Million USD | -2.4% |
| 2004 Q4 | 73.64 Million USD | -6.86% |
| 2003 FY | 31.58 Million USD | 0.34% |
| 2003 Q4 | 31.58 Million USD | 0.0% |
| 2002 FY | 31.47 Million USD | 108.23% |
| 2001 FY | 15.11 Million USD | -48.91% |
| 2000 FY | 29.59 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -10.247% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -1636.556% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 12.789% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -384.507% |
| Cosmos Health Inc. | 66.29 Million USD | -1404.016% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 36.668% |
| PainReform Ltd. | 9.93 Million USD | -9941.249% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -3546.094% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -3546.094% |
| SCYNEXIS, Inc. | 128.41 Million USD | -676.482% |
| Safety Shot Inc | 12.7 Million USD | -7745.479% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -4211.383% |
| Alpha Teknova, Inc. | 128.58 Million USD | -675.425% |
| Embecta Corp. | 1.21 Billion USD | 17.894% |
| Bright Green Corporation | 17.4 Million USD | -5629.433% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -36.908% |
| Journey Medical Corporation | 76.84 Million USD | -1197.474% |
| Procaps Group, S.A. | 460.18 Million USD | -116.672% |
| Theratechnologies Inc. | 77.76 Million USD | -1182.125% |
| Harrow Health, Inc. | 311.75 Million USD | -219.833% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -6595.065% |
| Biofrontera Inc. | 27.93 Million USD | -3469.726% |
| DURECT Corporation | 45.18 Million USD | -2106.502% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 29.233% |
| Cronos Group Inc. | 1.13 Billion USD | 12.092% |
| OptiNose, Inc. | 107.72 Million USD | -825.56% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -111.665% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1682.152% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -4226.334% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -116.748% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -8266.179% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -1119.3% |
| Radius Health, Inc. | 1.71 Billion USD | 41.892% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -1771.179% |
| ProPhase Labs, Inc. | 91.92 Million USD | -984.661% |
| Phibro Animal Health Corporation | 982.18 Million USD | -1.518% |
| Procaps Group S.A. | 460.18 Million USD | -116.672% |
| Alvotech | 950.09 Million USD | -4.948% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -2202.284% |
| Viatris Inc. | 47.68 Billion USD | 97.909% |
| Rockwell Medical, Inc. | 52.17 Million USD | -1811.134% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -744.317% |
| SIGA Technologies, Inc. | 254.83 Million USD | -291.269% |
| Tilray Brands, Inc. | 4.33 Billion USD | 77.001% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -264.3% |
| Shineco, Inc. | 84.17 Million USD | -1084.49% |
| PetIQ, Inc. | 868.22 Million USD | -14.843% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -11716.438% |
| Incannex Healthcare Limited | 17.04 Million USD | -5749.1% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 69.333% |
| Alimera Sciences, Inc. | 153.52 Million USD | -549.472% |
| Silver Spike Investment Corp. | 88.57 Million USD | -1025.692% |
| Assertio Holdings, Inc. | 286.41 Million USD | -248.125% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -16653.028% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -2850.355% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -3091.422% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -7426.651% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -281.845% |
| Hempacco Co., Inc. | 18.04 Million USD | -5426.196% |
| Talphera, Inc. | 20.39 Million USD | -4788.924% |
| Alvotech | 950.09 Million USD | -4.948% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -145.493% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 39.612% |
| Currenc Group, Inc. | 141.49 Million USD | -604.709% |
| Kamada Ltd. | 351.96 Million USD | -183.29% |
| Indivior PLC | 1.95 Billion USD | 48.899% |
| Evoke Pharma, Inc. | 7.06 Million USD | -14006.098% |
| Flora Growth Corp. | 23.62 Million USD | -4120.334% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -7426.651% |
| Evolus, Inc. | 188.99 Million USD | -427.57% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 22.088% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 34.094% |
| Akanda Corp. | 8.83 Million USD | -11179.375% |